$1.21 Billion Genital Herpes Market Insights, 2019: Epidemiology & Forecast to 2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 15, 2019--The “Genital Herpes - Market Insights, Epidemiology and Market Forecast - 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Genital Herpes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Genital Herpes from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography CoveredThe United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan
Study Period: 2017-2028
According to this research, the prevalent population of Genital Herpes was estimated to be 83,782,625 [7MM] in 2018. United States accounts for the highest Genital Herpes cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest prevalent patient population of Genital Herpes, followed by France.
There are currently three FDA approved anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States.
However these drugs have shown to be effective in managing the Genital Herpes frequent recurrence and healing of lesions but they are not fully potent in clearing the underline HSV infection.
Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space.
Detailed chapters for all of these marketed drugs along with late phase promising candidates like Pritelivir and GEN-003 have been covered in the report.
According to this research, the global market of Genital Herpes was estimated to be USD 1,211.3 million in 2018. The United States accounts for the largest market size of Genital Herpes, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The dynamics of Genital Herpes market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Genital Herpes. Upcoming therapies such as Pritelivir (Aicuris) and GEN-003 (Genocea), have the potential to create a significant positive shift in the Genital Herpes market size.
The market size of Genital Herpes includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Genital Herpes, several companies are working robustly on developing new therapies with novel mechanism of action.
Companies MentionedNovartis GlaxoSmithKline Genocea Biosciences AiCuris Maruho
Report InsightsPatient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies
Report Key Strengths10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition
Report AssessmentCurrent Treatment Practices Unmet Needs Detailed Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers
Key BenefitsThis report will help to develop Business Strategies by understanding the trends shaping and driving the Genital Herpes market. Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes market. To understand the future market competition in the Genital Herpes market.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qdr257/1_21_billion?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190215005146/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs,Sexual and Reproductive Health Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/15/2019 04:49 AM/DISC: 02/15/2019 04:49 AM